ArticleVirology journal2025
Predictors of low-level viremia in chronic hepatitis B and the efficacy of pegylated interferon-alpha: a real-world study.
Article in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Maintaining versus switching antiviral therapy in chronic hepatitis B patients with low-level viremia.Journal of virus eradication · 2026Article
- Virologic Response to Antiviral Therapy in Chronic Hepatitis B Patients With High Viral Load: A Real-World Cohort Study.Journal of viral hepatitis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLow-level viremia (LLV) is closely associated with the prognosis of patients with chronic hepatitis B (CHB), it can increase the incidence of cirrhosis and hepatocellular carcinoma. Our research aims to explore how to identify LLV early and implement effective therapeutic intervention.
methodsThis retrospective study included 720 patients who were either treatment-naive or had not received treatment within the past 5 years. After 48 weeks follow-up, they were categorized into either the complete virological response (CVR) or LLV. Independent risk factors associated with LLV were screened by LASSO regression analysis and a prediction model incorporating these factors was developed. Furthermore, among patients who developed LLV, we compared the therapeutic efficacy of nucleos(t)ide analogue (NAs) monotherapy and pegylated interferon alpha (IFNα)-based combination therapy.
resultsFirstly, four independent risk variables were found to be connected to the incidence of LLV, including age, baseline HBV DNA level, baseline HBsAg level, and baseline HBeAg status. The model showed AUCs of 0.861 (training) and 0.799 (validation), with good calibration. Secondly, between IFNα-based combination therapy and NAs monotherapy group, HBV DNA clearance rates showed no difference at week 24 but significant divergence at week 48 (p = 0.684 and p = 0.001). HBsAg decline rates (in patients with baseline HBsAg ≥ 1500 IU/mL) differed significantly at both 24/48 weeks (p < 0.001). Throughout the 48-week follow-up, the cumulative rates of HBV DNA clearance (p < 0.001), HBsAg loss (p < 0.001), HBeAg loss (p = 0.008), and HBeAg seroconversion (p = 0.001) were all significantly higher in the combination therapy group, though the cumulative HBsAg seroconversion rate was not (p = 0.535). Furthermore, stratified analysis confirmed the superior efficacy of IFNα-based combination therapy across key subgroups. It outperformed NAs monotherapy both in patients with HBsAg ≥ 1500 IU/mL (24w: p = 0.031; 48w: p = 0.002) and in those with HBV DNA < 500 IU/mL (24w: p = 0.01; 48w: p < 0.001).
conclusionAge, baseline HBV DNA level, HBsAg level, and HBeAg status were independently associated with the prevalence of LLV independently. Compared to NAs monotherapy, IFNα-based combination therapy in LLV patients demonstrated significantly higher rates of CVR, HBsAg decline, HBsAg loss/seroconversion, and HBeAg loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.